Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Status:
Active, not recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Anti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the
pre-operative setting with chemoradiation will be safe and feasible in patients with
resectable distal esophageal/gastroesophageal junction cancer and will change cellular and
molecular characteristics of the tumor microenvironment that will improve survival.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins